Growth hormone treatment affects brain neurotransmitters and thyroxine

DESIGN In a double‐blind, placebo‐controlled 21‐month trial with a cross‐over design, with each treatment period lasting for 9 months, we investigated the long‐term effect of GH on the cerebrospinal fluid concentrations of some brain neurotransmitters and thyroid hormones of importance for mood and cognition

P. Burman

2003

Scholarcy highlights

  • Analysis of cerebrospinal fluid collected at the end of the two treatment periods showed that the GH concentration was related to the administered dose of rhGH
  • DESIGN In a double‐blind, placebo‐controlled 21‐month trial with a cross‐over design, with each treatment period lasting for 9 months, we investigated the long‐term effect of GH on the cerebrospinal fluid concentrations of some brain neurotransmitters and thyroid hormones of importance for mood and cognition
  • Analysis of CSF collected at the end of the two treatment periods showed that the GH concentration was related to the administered dose of rhGH
  • After rhGH treatment the concentration of the dopamine metabolite homovanillic acid had decreased from 218 ± 80 to 193 ± 82 nmol/l and that of the excitatory acid aspartate had increased from 233 ± 81 to 313 ± 116 nmol/l
  • The concentration of total T3 was not measurable in CSF but increased in serum from 1.41 to 1.53 nmol/l
  • The study demonstrates a passage of GH from the circulation into the CSF
  • If the address matches an existing account you will receive an email with instructions to retrieve your username

Need more features? Save interactive summary cards to your Scholarcy Library.